Exited position

Ray Dalio’s Goodrx Hldgs Inc (GDRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2021Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares711.68KHighest verified quarter-end share count
Quarters reported8Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Goodrx Hldgs Inc in Q2 2021. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Bridgewater Associates, LP sold the entire position in Q2 2023, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2023
Sold the entire position−149.06K shares · No shares reported at quarter-end
Q1 2023
Sold 25.9% of the position−52.15K shares · 149.06K shares remained
Filing context

Quarter-end price $6.25 · Estimated holding basis $29.56

Q4 2022
Sold 10.5% of the position−23.60K shares · 201.22K shares remained
Filing context

Quarter-end price $4.66 · Estimated holding basis $29.56

Q3 2022
Sold 6.5% of the position−15.60K shares · 224.82K shares remained
Filing context

Quarter-end price $4.67 · Estimated holding basis $29.56

Q2 2022
Sold 1.0% of the position−2.36K shares · 240.42K shares remained
Filing context

Quarter-end price $5.92 · Estimated holding basis $29.56

Q1 2022
Bought 63.0% more+93.84K shares · 242.78K shares reported after the change
Filing context

Quarter-end price $19.33 · Estimated holding basis $29.56

Portfolio importance

How important was Goodrx Hldgs Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q1 2023
Last reported rank#572of 710 reported positions
Peak portfolio weight0.2%Q2 2021
Best historical rank#108Q2 2021
At peak importanceQ2 2021
GDRX
0.2%
Largest holding
5.4%
Cross-investor discovery

Who else owns Goodrx Hldgs Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
GDRX0.0% of reported portfolio
Explore Goodrx Hldgs Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.